Department news | December 28, 2021
The ECHO (Extension for Community Healthcare Outcomes) model uses a virtual educational lecture series and patient case discussion to improve provider preparedness to treat patients and improve patient outcomes. Our latest ECHO launch will test whether the model can enhance the care of traumatic brain injury (TBI).
KING 5 | November 17, 2021
A Mountlake Terrace clinic is using a novel therapy on some patients with treatment-resistant mental health challenges — but is it safe? Nathan Sackett, PhD, says psychedelics are only truly therapeutic when combined with professional psychotherapy.
Right as Rain | November 15, 2021
Microdosing psilocybin has become trendy among people hoping to alleviate anxiety or increase creativity. Nathan Sackett, MD, talks about its promise as a therapeutic agent and his plans to build a novel therapeutics research program that will explore the pairing of compounds like psilocybin and ketamine with behavioral interventions to treat addictions.
UW Medicine newsroom | October 26, 2021
Jeffrey Iliff, PhD, is co-PI of the first human trial of a device to speed up and enhance glymphatic function (brain cleansing) that occurs when we sleep. The trial is funded by the U.S. Department of Defense and based on research funded by the Garvey Institute for Brain Health Solutions. The story was covered in Patch, GeekWire, KXL, FOX 13, KOIN, and KIRO 7, among others.
Seattle Times | October 10, 2021
Debby Tsuang, MD, MSc, director of VA Puget Sound Health Care System’s Geriatric Research, Education, and Clinical Center, with funding from the Garvey Institute for Brain Health Solutions, is studying how Black adults ages 60-80 respond to three modes of screening for mental health concerns: through written forms, phone interviews or video calls.
Department news | September 30, 2021
We’re excited to announce that Marco Pravetoni, PhD, will be joining our department as the inaugural holder of the Rick L. Seaver Endowed Professorship for Brain Wellness funded by the Garvey Institute for Brain Health Solutions. Dr. Pravetoni is an expert in the development of vaccines, antibody-based strategies, and small molecules to counteract opioid use disorders and […]
Drug Discovery & Development | September 7, 2021
The University of Minnesota Medical School has developed a therapeutic vaccine for opioid use disorder that is the subject of a new Phase 1 randomized placebo-controlled clinical trial. Marco Pravetoni, PhD, is leading the drug discovery research and will join the UW Medicine Garvey Institute for Brain Health Solutions in 2022.
University of Washington Magazine | September 1, 2021
Washington has a shortage of mental-health workers and high demand for treatment. Funding from the Garvey Institute for Brain Health Solutions helps fast-track innovative treatments to turn the tide. Jürgen Unützer, MD, MPH, MA, Anna Ratzliff, MD, PhD, Ryan Kimmel, MD, Mollie Forrester, MSW, LICSW, and James Lee, MD, are quoted.
UW Medicine newsroom | June 8, 2021
Thomas Grabowski, MD, Director of the UW Medicine Alzheimer Disease Research Center and a member of the Garvey Institute’s Brain Health and Cognitive Aging workgroup, discusses the latest advances in Alzheimer’s Disease.
Committee for Children | June 1, 2021
Committee for Children’s text-based mentoring platform for new and expecting parents, Nurture Seattle, will benefit from a $100K Innovation Grant from the Garvey Institute for Brain Health Solutions. The project is led by Amritha Bhat, MBBS, MD, MPH.